Lenabasum for Systemic Sclerosis-Are Cannabinoids the Missing Link? Comment on the Article by Spiera et al.

We read with great interest the results of the trial of lenabasum in SSc. After many recent failed studies, we are excited to come across a positive drug trial in SSc. However, the systemic manifestations of the subjects i.e. pulmonary manifestations such as PH and ILD deserve a more detailed analysis, including their treatment response.